Citations

Clear

136 citation(s) found for "Para, R O".

Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world
Snyder, Heather M. , Tampi, Malavika P. , Aisen, Paul S., Allegri, Ricardo, Apostolova, Liana G., Atri, Alireza, Aurora, Sheena, Caramelli, Paulo, Cummings, Jeffrey, Fox, Nick C., Hardy, John, Lamb, Bruce T., Levey, Allan, Lopez, Oscar, Mummery, Catherine, Nitrini, Ricardo, Pahlke, Sarah, Petersen, Ronald C., Pike, K. Joanne, Porsteinsson, Anton P., Rabinovici, Gil D., Rafii, Michael, Raman, Rema, Sabbagh, Marwan N., Salloway, Stephen P., Scheltens, Philip, Schott, Jonathan M., Selkoe, Dennis J., Sevlever, Gustavo, Sperling, Reisa, Tansey, Malu Gamez, Dyck, Christopher van, Zetterberg, Henrik, Carrillo, Maria C., Hardy, John , Grinberg, Lea Tenenholz, Hardy, John , Aisen, Paul , Allegri, Ricardo , Apostolova, Liana G. , Atri, Alireza , Caramelli, Paulo , Crivelli, Lucía , Cummings, Jeffrey L. , Strooper, Bart De , Fox, Nick C, Grinberg, Lea T. , Lamb, Bruce T. , López, Oscar L. , Mummery, Catherine J. , Nitríni, Ricardo , Pahlke, Sarah , Petersen, Ronald C. , Porsteinsson, Anton P. , Rabinovici, Gil D. , Rafii, Michael S. , Raman, Rema, Salloway, Stephen , Scheltens, Philip , Schott, Jonathan M. , Selkoe, Dennis J. , Sevlever, Gustavo Emilio , Sperling, Reisa Anne , Tansey, Malú G. , Dyck, Christopher H. van , Zetterberg, Henrik , Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | July 28, 2026 | Volume: 22 | Issue: 7 | Pages: No page available

10.1002/alz.71696 | PMID 42516031 Get It

Abstract In response to a Cochrane review (published in April 2026) on the clinical trials of monoclonal antibodies targeting beta amyloid, this perspective outlines a number of critiques. The scientists, methodologists, subject‐matter experts, and clinicians on this perspective strongly recommend that the Cochrane editorial board consider a call for editorial response, correction of press materials, or commissioned reply to this review for four overarching reasons: (1) decision to pool antibodies that do and do not clear beta amyloid, (2) decision to include studies from a time when biomarkers of Alzheimer's disease were not available, (3) analytical and methodological limitations of the approach used, (4) conflating the distinct roles and methodological processes of systematic review and guideline methodologies, (5) contextualizing the present critique within the existing evidence‐synthesis literature, and (6) mechanistic inference beyond the scope of the presented analyses. Conclusions that may not accurately reflect treatment‐specific effects could cause significant downstream clinical and psychosocial harm to those currently undergoing treatment and their family members as well as individuals considering participation in Alzheimer's clinical trials.
Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
A, Prera Vilaseca, Bilodeau, Philippe, Gakis, Georgios , Savransky, Andrea, Oliveira, Joao Mahler Ferreira, Nguyen, Linda, Hooshmand, Sam I., Satyanarayan, Sammita , Moseley, Carson E., Haley, Leah , Roy-Hewitson, Chantal, Marrodan, M, Casallas, Adriana, Manín, Analisa , Chen, H, Grzezulkowska, Aniela, Contentti, Edgar Carnero, Galleguillos, Lorna, Upchurch, Margaret, Jackson-Tarlton, Caitlin S. , Guo, Joanne Chu-Yueh, Fabian, Michelle, Caparó-Zamalloa, César, Paterno, R, Waubant, Emmanuelle, Boschetti, Laura Ordoñez, Correale, Jorge, Villa, Andrés M., Banwell, Brenda, Marignier, Romain, Pittock, Sean J., Greenberg, Benjamin , Bennett, Jeffrey L., Cho, Tracey, Clardy, Stacey, Solomon, Andrew J., Ja, Gelfand, Obeidat, Ahmed Z., Blackburn, Kyle, Tenembaum, Silvia , Chen, John J., Sotirchos, Elias S., Levy, Michael, Flanagan, Eoin P., Group, and The Americas MOGAD Treatment, Murillo, Fabian, Syc-Mazurzek, Stephanie B., Jiang, Mulan , Rezende, N, Wingerchuk, D M, Horsman, Susan E. , Bilodeau, Philippe‐Antoine , Bilodeau, Philippe A , Vilaseca, Andreu , Hooshmand, Sam , Moseley, Carson E. , Marrodán, Mariano , Vanegas, Adriana Casallas , Hoshina, Yoji , Contentti, Edgar Carnero , Galleguillos, Lorna , Virupakshaiah, Akash , Arrambide, Georgina , Caparó‐Zamalloa, César , Waubant, Emmanuelle L. , Ordóñez-Boschetti, Laura, Villa, Andres Maria , Marignier, Romain , Pittock, Sean J. , Bennett, Jeffrey L. , Cho, Tracey , Clardy, Stacey , Solomon, Andrew , Kister, Ilya , Zamvil, Scott S. , Gelfand, Jeffrey M. , Repovic, Pavle , Obeidat, Ahmed Zayed , Blackburn, Kyle , Chen, John J., Sotirchos, Elias S. , Levy, Michael , Flanagan, Eoin P. , Syc‐Mazurek, Stephanie B. , Cacciaguerra, Laura , Rezende, Nathane Braga da Silva, Wingerchuk, Dean M.

Mayo Clinic

JAMA Neurology | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2220 | PMID 42440328 Get It

Importance Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) lacks proven relapse-preventive therapies. While clinical trials are ongoing, safety data may be limited and approved drugs are costly. Studies of interleukin 6 receptor blocker (IL-6RB) in MOGAD are limited by small numbers and no comparative studies, contributing to low use. Objective To evaluate the impact of IL-6RB therapy on relapse rates in MOGAD and compare relapse frequency with intravenous immunoglobulin (IVIG). Design, Setting, and Participants This international, multicenter, retrospective cohort study (January 1, 2015, through December 31, 2025) included a historical IVIG-treated cohort of varying doses. The study took place across sites in North and South America (US, Canada, Mexico, Argentina, Brazil, Chile, Colombia, and Peru). Patients with MOGAD (n = 116, no excluded patients) who received at least 1 dose of an IL-6RB were included. These data were analyzed in January 2026. Exposures Tocilizumab or satralizumab. Main Outcomes and Measures Annualized relapse rate (ARR) during IL-6RB therapy, time to next relapse after treatment initiation, and adverse events. Outcomes were compared with the IVIG cohort using inverse probability of treatment weighting (IPTW) adjusted for age, sex, prior ARR, and concomitant therapies. Results A total of 116 patients with MOGAD (89% relapsing) receiving IL-6RB (tocilizumab, 104 [90%] and satralizumab, 12 [10%]) were included; overall, 60.3% were female, 39.7% were male, and 18% were younger than 18 years. The median (IQR) IL-6RB treatment follow-up was 1.4 (0.7-2.5) years and 23 relapses occurred during 241.8 person-years of IL-6RB therapy. The ARR decreased from 0.64 (95% CI, 0.58-0.70) for relapsing MOGAD before IL-6RB to 0.09 (95% CI, 0.06-0.14) during IL-6RB treatment (incidence rate ratio, 0.08; 95% CI, 0.04-0.16). Adverse events occurred in 58 patients (50%), most commonly mild infections, although 10 (9%) had severe infections. In the IVIG cohort (n = 59), 30 relapses occurred over 133.8 person-years (ARR, 0.22; 95% CI, 0.15-0.32). After IPTW, IL-6RB was associated with a lower hazard ratio (HR) than the group who underwent IVIG therapy less than 1 g/kg every 4 weeks (HR, 4.5; 95% CI, 2.0-9.8), with no significant difference vs the group who underwent IVIG 1 g/kg or more every 4 weeks (HR, 2.0; 95% CI, 0.8-4.5). Conclusions and Relevance In this multicenter observational cohort, IL-6RB use in MOGAD was associated with low relapse rates and a favorable safety profile, though severe infections occurred occasionally. Relapse rates were lower than the group who underwent IVIG less than 1 g/kg every 4 weeks but not significantly different from the group who underwent IVIG 1 g/kg or more every 4 weeks. This supports IL-6RB as a potential relapse-prevention therapy in MOGAD; the wide availability and relative affordability of tocilizumab may enable broad global use.
A76-17 Physical Attributes and Tissue Deposition of Aerosolized Delivery of Exosome Particles via Inhaled Route in Spontaneous Breathing Mice
Khan, I, Wang, S, Erickson, B E, Wang, W, Para, R O, Paradise, C R, Stalboerger, P G, Behfar, A, Vassallo, R, Stalboerger, Paul G., Behfar, Atta , Vassallo, R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5361 Get It

Abstract Introduction The inhalation of aerosolized therapeutics is a promising strategy for the targeted delivery of drugs and biologics to the lungs. We have previously demonstrated the efficacy and feasibility of nebulized exosomes using a platelet-derived exosome product (PEP: Rion, Inc.), which significantly attenuated emphysema in a murine model (PMID: 38325750). However, the PEP aerosol’s physical properties—such as size, tissue deposition, anatomic location, and stability remain incompletely characterized. To address this, we utilized a cascade impactor to define aerosol particle size and deposition patterns and employed immunofluorescence staining to assess the regional and anatomic localization of nebulized PEP within the murine lung. Methods PEP particle size and tissue deposition were determined by passing the aerosol through a Marple cascade impactor (CI, DSI), which was connected to an inhalation tower (DSI). PEP aerosols were generated by a vibrating mesh nebulizer (Aerogen, Cat No AG-AL1100) at a controlled velocity and humidity and delivered to the CI at a flow rate of 2L/min. Aerosols were separated by size and allowed to deposit at the corresponding stages as they passed through the pinholes of the stage, by design. The stages were weighed after nebulization, and the percentage of aerosol deposition was calculated to simulate the human respiratory tree, according to the manufacturer’s specifications. In parallel, fluorescence DiR-labeled PEP was nebulized to spontaneously breathing mice, and confocal microscopy was used to determine intrapulmonary distribution. Results A total of 2.25 mL of PEP reconstituted in 0.9% normal saline (11.4 mg/mL final concentration) was nebulized for 35 minutes at a flow rate of 2 L/min, yielding 3.5 mg of total aerosol deposition, which is 13.6% of the total PEP mass (25.65mg) being nebulized, across the CI stages. Of this, 74% of the aerosolized particles with a particle size ≤ 1µm and deposited in Stages 7, 8 & F, corresponding to the deep regions of the lungs, specifically regions beyond the alveolar ducts and within the alveoli. In vivo 3D confocal imaging corroborated these findings, revealing abundant DiR-labeled PEP deep into the alveolar space within the peripheral regions of all lung lobes. Conclusion The study result demonstrates the feasibility and capability of delivering aerosolized PEP deeply into the alveolar regions of the lung at the given pressure, humidity, flow rate and nebulizer settings. This study establishes a methodological framework for characterizing and optimizing aerosolized exosome therapeutics for precise, region-specific delivery within the respiratory tract. This abstract is funded by: Department of Defense, Mayo Clinic Funding
B76-20 Nebulized Platelet-derived Extracellular Vesicles Attenuate Serpina1 Ko Mice Emphysema Induced by Cigarette Smoke
Wang, W , Wang, S, Erickson, B E, Para, R O, Khan, I A, Paradise, C R, Stalboerger, P G, Behfar, A, Vassallo, R, Erickson, B E, Khan, I, Stalboerger, Paul G., Behfar, Atta , Vassallo, Robert

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1871 Get It

Abstract Rationale Alpha1-antitrypsin (AAT; gene name SERPINA1) is a critical antiprotease that protects the lung from neutrophil elastase-mediated injury. AAT deficiency predisposes to emphysema, which is further exacerbated by cigarette smoke (CS) exposure. We previously reported (PMID: 38325750) that a nebulized human platelet-derived exosome product (PEP) attenuated CS-induced emphysema in C57BL/6 mice. Given the presence of AAT protein in these platelet-derived exosomes (identified by proteomics), we hypothesized that PEP nebulization would significantly attenuate both spontaneous and CS-induced emphysema in SERPINA1 knockout (KO) mice. Methods Transgenic SERPINA1 KO C57BL/6 mice (both sexes) exposed to CS (10 cigarettes/day and 5 days/week) for 2 months were then randomized to receive nebulized PEP or 0.9% saline (placebo) twice weekly for 4 additional weeks, with continued CS exposure. PEP was reconstituted in 0.9% saline (22.7mg/mL; ∼3 × 10¹0 vesicles/mL) and administered via pressure- and humidity-controlled nose-only inhalation tower (2.25 mL of PEP or saline over 35 minutes). Lung static compliance (Cst), cutaneous O2 saturation, mean linear intercepts (Lm), and plethysmographic parameters were measured during and after the study. Results Histological analysis of the lung tissue sections revealed that PEP significantly attenuated the CS-induced increase in alveolar size, as determined by measurement of the mean linear intercepts (Lm, p < 0.001). Lung static compliance (Cst), which was increased in CS-exposed mice, was also significantly decreased in the PEP-treated group (p < 0.001) compared to placebo in the male and female combined group. Functional respiratory parameters further supported the protective effect of PEP in this AAT-deficient model. In female mice, PEP nebulization significantly improved several CS-impaired pulmonary function parameters, including minute volume (MV, p = 0.024), the flow at the point 50% of tidal volume is expired (EF50, p = 0.021), Peak Inspiratory Flow (PIF, p = 0.009), Peak Expiratory Flow (PEF, p = 0.018), and O2 saturation (p = 0.035). However, these improvements were not observed in male mice. Conclusions These findings extend prior observations and underscore the therapeutic potential of nebulized AAT-enriched PEP directly to the alveolar region, effectively attenuating injury and improving pulmonary function in AAT deficiency-related emphysema. This abstract is funded by: Department of Defense, Mayo Clinic Funding, The Young and Middle-aged Medical High-end Talents in Chongqing Program
B76-17 Orchestrated Thy1-itgax_itgb2 / Ptprc-mrc1 and Lamc1-cd44 Signaling Pathways as Molecular Checkpoints for Alveolar Macrophage Activation Under Oxidative Stress
Erickson, B E, Wang, S, Du, Z, Para, R O, Liu, M, Stalboerger, P G, Paradise, C R, Behfar, A, Vassallo, R, Stalboerger, Paul G., Behfar, Atta , Vassallo, R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1868 Get It

Abstract Introduction We previously demonstrated that nebulized platelet-derived exosome product (PEP) alleviates cigarette smoke (CS)-induced murine emphysema. To elucidate the underlying molecular mechanisms, we conducted single-nucleus RNA sequencing of lung tissue, which initially revealed a shift in the cell source for TNF signaling (a critical regulator of inflammation in COPD lungs) from innate lymphoid cells (ILC) to alveolar macrophages (aMac) after chronic CS exposure. In this study, we conducted a more in-depth analysis of cellular communication to determine the mechanism by which PEP modulates CS-induced TNF signaling in the lung microenvironment. Methods Single-cell transcriptomics and cell-cell communication analyses were performed between CS-exposed placebo control lungs vs. sham control lungs and CS-exposed PEP-treated vs. placebo control lungs using R packages, including Seurat, CellChat, Patchwork, Future, and NMF. A comparative analysis of ligand-receptor interactions across these datasets was conducted using CellChat to infer intercellular signaling networks. Results Single-nuclear RNA-seq analysis revealed that the Thy1-ITGAX_ITGB2 signaling pathway was significantly upregulated by CS, acting as the adhesive and activating bridge that facilitates the switch in TNF production from ILC to aMac. Thy1 is a GPI-anchored ligand expressed on ILCs, and ITGAX_ITGB2 is its cognate receptor on aMacs. Concurrently, Ptprc-Mrc1 signaling, an inhibitory pathway in ILC-aMac crosstalk, was downregulated, contributing to sustained aMac activation by CS. Furthermore, analysis of aMac-aMac interactions revealed upregulated GRN/Sort1 signaling, which promotes the internalization of progranulin, an anti-inflammatory glycoprotein that competes for TNF/TNFR signaling. Ptprc-Mrc1 signaling was also downregulated within the aMac autocrine/paracrine network, further perpetuating a pro-inflammatory state. In contrast, treatment with PEP downregulated Thy1-ITGAX_ITGB2 signaling and upregulated Lamc1-Cd44 signaling, a hallmark of aMac deactivation, thereby inducing a phenotypic switch in inflammatory macrophages toward a reparative M2 state, promoting the resolution of CS-induced chronic inflammation. Conclusions These data suggest that the transition of TNF production from ILCs to aMacs under chronic CS stress is driven by increased Thy1-ITGAX_ITGB2 interactions and decreased Ptprc-Mrc1 signaling between ILCs and aMacs crosstalk within the local tissue. Enhancing the crosstalk between Lamc1-Cd44 and Ptprc-Mrc1 may suppress TNF production and attenuate CS induced aMac activation. Targeting these pathways, as demonstrated by nebulized PEP treatment, holds therapeutic potential to deactivate inflamed aMacs and promote homeostasis in the inflamed lung. This abstract is funded by: Department of Defense, Mayo Clinic Funding
Beard Dermatitis Due to Allergic Contact Dermatitis to Para-Phenylenediamine in Arabic Men.
Hsu, Te‐Shao, DAVIS, M, el-Azhary, Rokea, Gibson, Lawrence, el‐Azhary, Rokea A. , Gibson, Lawrence E.

Mayo Clinic

American Journal of Contact Dermatitis | April 17, 2026 | Volume: 11 | Issue: 4 | Pages: 256-256

10.1053/ajcd.2000.3063 Get It

Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease
Llibre‐Guerra, Jorge J. , Lu, Ruijin , Clarens, Ma. Florencia, Liu, Ian, Renton, Alan, Ryan, Natalie S. , Goate, Alison , Aguillón, David , Benzinger, Tammie L.S. , Chhatwal, Jasmeer P. , Chrem-Méndez, Patricio , Vigo, Gabriela , Farlow, Martin R., Huey, Edward D. , Perrin, Richard J. , Wang, Guoqiao, Li, Yan, Xiong, Chengjie, Daniels, Alisha , Goate, Alison M , Benzinger, Tammie L S , Berman, Sarah , Chhatwal, Jasmeer , Chrem Mendez, Patricio , Vigo, Gabriela , Cruchaga, Carlos , Day, Gregory S , Fox, Nick C , Gordon, Brian A , Hassenstab, Jason , Huey, Edward D , Ibanez, Laura , Ikeuchi, T , Jucker, Mathias , Lee, Jae‐Hong , Levey, Allan I , Xiong, Chengjie , Niimi, Yoshiki , Perrin, Richard , Rosa-Neto, Pedro , Sánchez-Valle, Raquel , Schofield, Peter R , Morris, John C , Karch, Celeste M , Daniels, Alisha , McDade, Eric M , Bateman, Randall J , Llibre-Guerra, Jorge J , Aguillon, David , Clarens, María Florencia , Renton, Alan , Allegri, Ricardo , Berman, Sarah , Day, Gregory S. , Farlow, Martin R. , Fox, Nick C. , Gordon, Brian A. , Hassenstab, Jason , Ikeuchi, Takeshi , Levey, Allan I. , Xiong, Chengjie , Sánchez‐Valle, Raquel , Schofield, Peter R. , Wang, Guoqiao , Li, Yan , Xiong, Chengjie , Morris, John C. , Karch, Celeste M. , McDade, Eric , Bateman, Randall J.

Mayo Clinic

Neurology | April 8, 2026 | Volume: 106 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000214804 | PMID 41950468 Get It

Abnormalities in core AD biomarkers precede inflammatory and glial markers in CSF in Autosomal Dominant Alzheimer’s Disease
Lin, Wenjing , Beric, Aleksandra , Baker, Bryce, Jerome, Gina, Minton, Matthew, Preminger, Sam Rose, Stauber, Jennifer, Schindler, Suzanne E, Dage, Jeff L., Aguillon, David, Benzinger, Tammie L.S., Chhatwal, Jasmeer, Daniels, Alisha , Day, Gregory, Devenney, Emma , Fox, Nick, Goate, Alison, Gordon, Brian A., Barthélemy, Nicolas R., Hassenstab, Jason, Huey, Edward D. , Jayadev, Suman, Ishiguro, Takanobu , Lee, Jae-Hong, Levey, Allan I., Levin, Johannes, Morris, John C, Perrin, Richard J., Renton, Alan E., Xiong, Chengjie, Ances, Beau M., McDade, Eric, Network, Dominantly Inherited Alzheimer, Dage, Jeffrey L. , Wisch, Julie K , Dage, Jeffrey L , Allegri, Ricardo , Aguillon, David , Benzinger, Tammie L S , Chhatwal, Jasmeer , Daniels, Alisha , Day, Gregory S , Goate, Alison M , Gordon, Brian A , Huey, Edward D , Ikeuchi, T , Jucker, Mathias , Ishiguro, Takanobu , Roh, Jee Hoon , Bateman, Randall J , Cruchaga, Carlos , Karch, Celeste M , Supnet-Bell, Charlene , Llibre-Guerra, Jorge J , Ibanez, Laura , Wisch, Julie K. , Baker, Bryce, Schindler, Suzanne E. , Allegri, Ricardo , Benzinger, Tammie L.S. , Chhatwal, Jasmeer P. , Day, Gregory S. , Fox, Nick C. , Goate, Alison , Gordon, Brian A. , Barthélemy, Nicolas R. , Hassenstab, Jason , Ikeuchi, Takeshi , Jayadev, Suman , Levey, Allan I. , Xiong, Chengjie , Morris, John C. , Perrin, Richard J. , Renton, Alan , Roh, Jee Hoon , Xiong, Chengjie , Bateman, Randall J. , Ances, Beau M. , Karch, Celeste M. , Supnet, Charlene , Llibre‐Guerra, Jorge J. , McDade, Eric , Network, Dominantly Inherited Alzheimer

Mayo Clinic

No container title available | April 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.31.26349851 | PMID 41959774 Get It

ABSTRACT BACKGROUND Increasing evidence suggests that accurate prediction of Alzheimer’s disease (AD) symptom onset requires more than amyloid- and tau-centric biomarkers such as cerebrospinal fluid (CSF) Aβ42/40, total tau and p-tau181 and plasma p-tau217. Autosomal dominant AD (ADAD), caused by pathogenic PSEN1, PSEN2 and APP mutations with predictable age at symptom onset, presents a unique opportunity to characterize the chronological changes in proteins beyond amyloid and tau and clarify them as early biomarkers of disease onset or as biomarkers related to disease staging and progression monitoring. METHODS We measured 972 CSF samples corresponding to 484 participants of the Dominantly Inherited Alzheimer Disease Network (DIAN) using the NULISASeq 120 CNS Disease Panel. We first benchmarked the technology against gold-standard measurements followed by the identification of proteins that were differentially abundant in relation to mutation status and symptomatology. Next, we determined the chronological emergence of protein changes in relation to the estimated years to onset (EYO). Finally, we assessed whether specific protein measures improved the prediction of EYO in the ADAD. FINDINGS NULISA measurements were comparable to those previously published. We demonstrated that known early alterations in CSF amyloid and tau were followed by inflammatory and neurodegenerative responses suggesting that clinical manifestation of AD happens before the inflammatory processes is fully developed. Finally, we found a multi-protein composite approach for predicting EYO that outperformed single biomarker values. INTERPRETATION Our results suggest that the main CSF proteomic landscape changes in ADAD are due to the presence of a pathogenic mutation and occur prior to symptom onset. Improved performance of multi-protein composite to predict EYO compared to single biomarker values highlights the added value of multiplex proteomic signatures for biomarker panel development. FUNDING National Institute on Aging, Alzheimer’s Association, German Center for Neurodegenerative Diseases, Raul Carrea Institute for Neurological Research, Japan Agency for Medical Research and Development, Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea, Spanish Institute of Health Carlos III.
The landscape of dementia research, diagnosis, treatment, and care in Latin America
Suemoto, Claudia K., Custodio, Nilton, Avila‐Funes, José A., Baez, Sandra, Bagnati, Pablo , Barnes, Lisa Laverne, D., Brucki Sonia M., Calandri, Ismael L., Cornejo‐Olivas, Mario, Derio, Carolina Delgado, García, Adolfo M., Grinberg, Lea T., Ibanez, Agustin M., Isasi, Rosario, Josephy‐Hernandez, Sylvia , Porras, Maria Lazo, Llibre‐Guerra, Jorge J., Llibre‐Rodriguez, Juan J., Meza, B. Marcela Mar, Migeot, Joaquin, Miranda, J. Jaime, Miranda‐Castillo, Claudia, Mummery, Catherine J., Parodi, José F., Castro, Natalia Pozo, Contreras, Rosa María Salinas, Slachevsky, Andrea, Souza‐Talarico, Juliana Nery, Takada, Leonel T., Tsoy, Elena, Pilalumbo, Martha Unaucho, Zimmer, Eduardo R., Fontana, Igor C. , Snyder, Heather M. , Carrillo, Marı́a C., Carrillo, María C. , Takada, Leonel Tadao , Custodio, Nilton , Ibáñez, Agustín , Suemoto, Cláudia Kimie , Delgado, Carolina , Mahinrad, Simin , Ibañez, Agustín , Suemoto, Claudia Kimie , Aguilar, Diego, Ávila‐Funes, José Alberto , Báez, Sandra , Barnes, Lisa L. , Brucki, Sônia Maria Dozzi , Caramelli, Paulo , Cornejo-Olivas, Mario , Ferreira, Sérgio T. , García, A.R. , Grinberg, Lea T. , Llibre‐Guerra, Jorge J. , Rodríguez, Juan J. Llibre , Lourenco, Mychael V. , Migeot, Joaquín , Miranda, J. Jaime , Miranda‐Castillo, Claudia , Mummery, Catherine J. , Parodi, Jose Francisco , Salinas‐Contreras, Rosa Maria, Santamaría‐García, Hernando A , Slachevsky, Andrea , Souza‐Talarico, Juliana Nery , Surace, Ezequiel , Tsoy, Elena , Unaucho‐Pilalumbo, Martha , Zimmer, Eduardo Rigon , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia | March 27, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71309 | PMID 41894159 Get It

Abstract Latin America is undergoing rapid population aging alongside a rising burden of dementia. While the region holds substantial potential for dementia risk reduction, challenges remain, such as delayed diagnoses, limited access to specialized care and biomarker testing, persistent stigma, and deep‐rooted structural inequities. To address these gaps and foster regionally informed solutions, the Alzheimer's Association convened the 2025 Alzheimer's Association International Conference (AAIC) Satellite Symposium in Lima, Peru, on May 14–15, in collaboration with the Global Brain Health Institute (GBHI) and the Atlantic Fellows for Equity in Brain Health. The meeting aimed to bring core elements of the global AAIC meeting to regional Latin American settings, recognizing that national and cultural contexts demand tailored approaches to dementia prevention, risk reduction, treatment and care all aimed at promoting brain health in the region. This manuscript synthesizes the symposium's key discussions, scientific advances, and opportunities for collaboration across the region.
Abstract PD4-07: Association between age at diagnosis and survival among young BRCA carriers with breast cancer: results from an international multicenter hospital-based cohort study
Meacci, Arianna , Gil, M. Fragío, Klocker, E., Coussy, Florence , Kim, H., Molho, R. Bernstein, Meglio, A. Di, Pogoda, K., Bajpai, J. , Wildiers, Hans, Balmana, J., Moore, H. C., Phillips, K., Partridge, A. H., Rousset-Jablonski, C., PeccatorI, F. A., Toss, Angela, Renaud, T., Anghelone, Chiara Annunziata Pasqualina, Cruz, A. Benitez, Lee, J. E., Fruscio, R, Cui, W., Wong, S. M., Lee, M., Rozenblit, M., Villarreal-Garza, C., Matikas, A., Dieci, M. V., Marchis, Laura De , Plichta, J. K., Ruddy, K. J., Guven, D. Can, Puglisi, F., Kemp, Zoë, Meireles, P. A., Delucchi, Virginia , Lambertini, M., Blondeaux, Eva , Gil, Mónica Fragío , Molho, R. Bernstein, Hilbers, Florentine , Meglio, Antonio Di , Kwong, Ava , Pogoda, K. , Agostinetto, Elisa , Moore, Halle C F , Partridge, Ann H. , Rousset‐Jablonski, Christine , Peccatori, Fedro A , Toss, Angela , Renaud, Tiphaine , Paluch–Shimon, Shani , Rozenblit, M., Vernieri, Claudio , Villarreal‐Garza, Cynthia , Matikas, Alexios , Plichta, J. K., Ruddy, Kathryn J. , Puglisi, Fabio , Kemp, Z.E., Meireles, P., Mastro, Lucia Del , Lambertini, Matteo

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD4-07-PD4-07

10.1158/1557-3265.sabcs25-pd4-07 Get It

Abstract Background Young age is a known risk factor for breast cancer recurrence and mortality, particularly in hormone receptor-positive disease. However, no specific evidence exists on whether age at diagnosis influences clinical behavior and outcomes among carriers of germline BRCA pathogenic or likely pathogenic variants (PVs). Methods The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, hospital-based, retrospective cohort study including women with germline BRCA1 and/or BRCA2 PVs and diagnosed with stage I-III breast cancer at the age of 40 years or younger between January 2000 and December 2020. The present analysis aimed to evaluate clinical features and outcomes of breast cancer in young BRCA carriers according to age at diagnosis, by comparing patients aged ≤30 years with those aged 31-35 and 36-40 years at breast cancer diagnosis. The primary endpoint was disease-free survival (DFS). Overall survival (OS) was a secondary endpoint. Multivariable Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs), adjusting for risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) (time-dependent), and stratifying by country, year of diagnosis, tumor size, nodal involvement, tumor grade and hormone receptor status. Results From 109 centers in 5 continents, 5350 young BRCA carriers were included, of whom 1106 (20.7%) were ≤30 years of age, 1945 (36.4%) were 31-35 years and 2299 (43.0%) were 36-40 years at the time of breast cancer diagnosis. Compared to patients aged 31-35 and 36-40 years, those aged ≤30 years were more likely to harbor BRCA1 PVs (71.3%, 62.4%, 61.1%, respectively), to present with high-grade (G3 in 71.3%, 66.6%, 65.0%, respectively), triple-negative breast cancer (56.3%, 48.1%, 46.6%, respectively), and less frequently smaller tumor size (T1: 31.7%, 36.6% and 39.5%, respectively). Consequently, chemotherapy was administered more frequently among patients aged ≤30 years (94.4%, 92.6%, 89.7%, respectively). At a median follow-up of 8.2 years (IQR, 4.7-12.8), 8-year DFS rate was 65.0% among patients aged ≤30 years, 64.7% in the 31-35 years group, and 65.8% in the 36-40 years group. No significant association between age at diagnosis and DFS outcome was observed (31-35 vs. ≤30 years: aHR 1.03, 95% CI 0.89-1.19; 36-40 vs. ≤30 years aHR 1.00, 95% CI 0.87-1.16). Similarly, no significant association between age at diagnosis and OS was observed (31-35 vs. ≤30 years: aHR 1.10, 95% CI 0.86-1.41; 36-40 vs. ≤30 years: aHR 1.11, 95% CI 0.87-1.43). Subgroup analyses by specific BRCA gene, tumor subtype, tumor size, nodal status, and chemotherapy use revealed no statistically significant interaction with age at diagnosis in terms of DFS or OS (all p for interaction > 0.05). Specifically, no significant differences between age groups were observed among patients with luminal-like tumors for both DFS and OS. Conclusions In this unique international cohort of BRCA carriers diagnosed with breast cancer at a young age (≤40 years), we found no significant differences in DFS nor OS across different age groups. Notably, very young age (≤30 years) at diagnosis was not associated with worse outcomes compared to 31-35 years or 36-40 years. Age per se should not be considered a negative prognostic factor in BRCA carriers when appropriate treatment is provided. Citation Format: E. Blondeaux, A. Meacci, M. Fragío Gil, E. Klocker, F. Coussy, H. Kim, R. Bernstein Molho, F. Hilbers, A. Di Meglio, A. Kwong, K. Pogoda, J. Bajpai, H. Wildiers, E. Agostinetto, J. Balmana, H. C. Moore, K. Phillips, A. H. Partridge, C. Rousset-Jablonski, F. A. Peccatori, A. Toss, T. Renaud, C. Anghelone, A. Benitez Cruz, S. Paluch-Shimon, J. Lee, R. Fruscio, W. Cui, S. M. Wong, M. Lee, M. Rozenblit, C. Vernieri, C. Villarreal-Garza, A. Matikas, M. Dieci, L. De Marchis, J. K. Plichta, K. J. Ruddy, D. Can Guven, F. Puglisi, Z. Kemp, P. A. Meireles, L. Del Mastro, V. Delucchi, M. Lambertini. Association between age at diagnosis and survival among young BRCA carriers with breast cancer: results from an international multicenter hospital-based cohort study [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD4-07.